Skip to main content
Clinical Trials/NCT05769699
NCT05769699
Recruiting
Not Applicable

Serum Biomarkers in Parkinson's Disease at Different Stages

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country200 target enrollmentFebruary 10, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
200
Locations
1
Primary Endpoint
Determine clinical characteristics of parkinsonian patients in various stages of disease
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

  • Determine clinical characteristics of parkinsonian patients in various stages of disease;
  • Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease.
  • Measure vesicular neurodegeneration, synaptic and inflammation biomarkers
Registry
clinicaltrials.gov
Start Date
February 10, 2022
End Date
November 30, 2027
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with idiopathic PD according to Movement Disorders Society (MDS) criteria;
  • Age: 18-80 years;
  • Signature of informed consent to participate in this study
  • Exclusion criteria.
  • Women pregnant
  • Inflammatory or autoimmune diseases

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Determine clinical characteristics of parkinsonian patients in various stages of disease

Time Frame: 3 years

Determine clinical characteristics of parkinsonian patients in various stages of disease by means of NMS score changes.

Determine biooogical characteristics of parkinsonian patients in various stages of disease

Time Frame: 3 years

dosage of serum IL-1b, IL6, IL-5, IL-4, IL17, TNFa, IFNg, IL10, total-alpha-synuclein, NfL, BDNF (ng/ml for all)

Study Sites (1)

Loading locations...

Similar Trials